RecruitingNot ApplicableNCT04501705

Apatinib in the Treatment of Recurrent Atypical/malignant Meningioma in Adults

Clinical Study of Apatinib in the Treatment of Recurrent Atypical/malignant Meningioma in Adults

Sponsor

Beijing Sanbo Brain Hospital

Enrollment

29 participants

Start Date

Aug 18, 2020

Study Type

INTERVENTIONAL

Conditions

Recurrent Atypical/malignant Meningioma

Summary

Apatinib mesylate may be an effective treatment for recurrent atypical/malignant meningioma. This prospective clinical study is now planned to verify the effectiveness and safety of apatinib mesylate in the treatment of relapsed atypical/malignant meningioma.

Eligibility

Min Age: 18 YearsMax Age: 70 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Apatinib Mesylate for people with recurrent atypical/malignant meningioma. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years to 70 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGApatinib Mesylate

Apatinib mesylate tablets: Orally, 500 mg, once a day, with warm water for half an hour after a meal (the time of taking the medicine every day should be the same as possible). Continue to use 28 days as a cycle, medication until disease progression (PD), intolerable toxicity occurs or the patient withdraws informed consent. However, the longest period does not exceed 24 cycles, and the treatment after 24 cycles is determined by the investigator.

Locations(1)

Sanbo Brain Hospital

Beijing, Beijing Municipality, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT04501705